BBP-398

DRUG4 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Navire Pharma Inc., a BridgeBio company, LianBio LLC

Conditions

Advanced Solid TumorAdvanced or Metastatic Non-small Cell Lung CancerMetastatic NSCLCMetastatic Solid TumorNSCLCNSCLC and CRCNon Small Cell Lung CancerOncology

Phase 1

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

TerminatedNCT05480865

Navire Pharma Inc., a BridgeBio companyMetastatic NSCLC, Metastatic Solid Tumor, Non Small Cell Lung Cancer +1

Start: 2022-07-06End: 2024-08-22Updated: 2024-12-12

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

TerminatedNCT05621525

LianBio LLCAdvanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumor

Start: 2022-10-18End: 2024-03-29Updated: 2024-06-25

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

TerminatedNCT06032936

LianBio LLCNSCLC

Start: 2023-07-27End: 2024-03-29Updated: 2024-06-25

Phase 1/2 Open-label Study of BMS-986466 in Combination with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Advanced Solid Tumors

CompletedCTIS2023-505070-15-00

Bristol-Myers Squibb Services Unlimited CompanyNSCLC and CRC, Oncology

End: 2024-03-15Target: 62Updated: 2024-03-15